News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
275,658 Results
Type
Article (14340)
Company Profile (101)
Press Release (261208)
Multimedia
Podcasts (69)
Webinars (14)
Section
Business (88354)
Career Advice (474)
Deals (15406)
Drug Delivery (76)
Drug Development (36743)
Employer Resources (50)
FDA (6396)
Job Trends (6237)
News (150841)
Policy (14139)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (446)
Accelerated approval (17)
Adcomms (8)
Allergies (83)
Alliances (23327)
ALS (63)
Alzheimer's disease (496)
Antibody-drug conjugate (ADC) (120)
Approvals (6628)
Artificial intelligence (230)
Autoimmune disease (61)
Automation (16)
Bankruptcy (151)
Best Places to Work (4371)
BIOSECURE Act (9)
Biosimilars (131)
Biotechnology (39)
Bladder cancer (44)
Brain cancer (35)
Breast cancer (184)
Cancer (1473)
Cardiovascular disease (177)
Career advice (424)
Career pathing (13)
CAR-T (54)
CDC (6)
Cell therapy (168)
Cervical cancer (12)
Clinical research (32246)
Collaboration (824)
Compensation (351)
Complete response letters (41)
COVID-19 (781)
CRISPR (46)
C-suite (523)
Cystic fibrosis (60)
Data (2105)
Decentralized trials (1)
Denatured (18)
Depression (52)
Dermatology (11)
Diabetes (140)
Diagnostics (1411)
Digital health (10)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (136)
Drug pricing (116)
Drug shortages (13)
Duchenne muscular dystrophy (90)
Earnings (33839)
Editorial (22)
Employer branding (4)
Employer resources (46)
Events (39318)
Executive appointments (567)
FDA (7615)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (3)
Funding (484)
Gene editing (75)
Generative AI (22)
Gene therapy (183)
GLP-1 (459)
Government (1416)
Grass and pollen (4)
Guidances (169)
Healthcare (3593)
HIV (16)
Huntington's disease (9)
IgA nephropathy (45)
Immunology and inflammation (78)
Immuno-oncology (21)
Indications (73)
Infectious disease (863)
Inflammatory bowel disease (82)
Inflation Reduction Act (7)
Influenza (28)
Intellectual property (122)
Interviews (62)
IPO (5915)
IRA (33)
Job creations (2057)
Job search strategy (379)
JPM (29)
Kidney cancer (10)
Labor market (29)
Layoffs (206)
Leadership (8)
Legal (3450)
Liver cancer (24)
Longevity (8)
Lung cancer (201)
Lymphoma (136)
Machine learning (13)
Management (17)
Manufacturing (463)
MASH (78)
Medical device (1317)
Medtech (1328)
Mergers & acquisitions (9944)
Metabolic disorders (495)
mRNA (55)
Multiple sclerosis (52)
NASH (15)
Neurodegenerative disease (94)
Neuropsychiatric disorders (43)
Neuroscience (958)
Neurotech (1)
NextGen: Class of 2026 (1589)
Non-profit (614)
Now hiring (21)
Obesity (258)
Opinion (146)
Ovarian cancer (46)
Pain (123)
Pancreatic cancer (57)
Parkinson's disease (92)
Partnered (11)
Patents (245)
Patient recruitment (140)
Peanut (14)
People (29957)
Pharmaceutical (60)
Pharmacy benefit managers (18)
Phase 1 (8362)
Phase 2 (13625)
Phase 3 (12295)
Pipeline (2605)
Policy (142)
Postmarket research (1401)
Preclinical (3370)
Press Release (25)
Prostate cancer (95)
Psychedelics (17)
Radiopharmaceuticals (141)
Rare diseases (413)
Real estate (2660)
Recruiting (19)
Regulatory (11139)
Reports (15)
Research institute (580)
Resumes & cover letters (57)
Rett syndrome (7)
RNA editing (6)
RSV (23)
Schizophrenia (79)
Series A (95)
Series B (56)
Service/supplier (2)
Sickle cell disease (51)
Special edition (10)
Spinal muscular atrophy (84)
Sponsored (10)
Startups (1656)
State (2)
Stomach cancer (6)
Supply chain (53)
Tariffs (68)
The Weekly (49)
Vaccines (250)
Venture capital (35)
Weight loss (151)
Women's health (37)
Worklife (4)
Date
Today (34)
Last 7 days (248)
Last 30 days (974)
Last 365 days (10386)
2026 (2664)
2025 (10723)
2024 (12507)
2023 (14265)
2022 (19566)
2021 (20069)
2020 (19038)
2019 (14892)
2018 (11723)
2017 (13896)
2016 (13132)
2015 (15477)
2014 (12425)
2013 (10596)
2012 (11404)
2011 (11931)
2010 (10896)
Location
Africa (319)
Alabama (19)
Alaska (1)
Arizona (81)
Arkansas (4)
Asia (21034)
Australia (2702)
California (3502)
Canada (1603)
China (622)
Colorado (154)
Connecticut (136)
Delaware (135)
Europe (41219)
Florida (664)
Georgia (68)
Hawaii (1)
Idaho (10)
Illinois (388)
India (51)
Indiana (266)
Iowa (2)
Japan (289)
Kansas (80)
Kentucky (21)
Louisiana (6)
Maine (2)
Maryland (457)
Massachusetts (2823)
Michigan (49)
Minnesota (184)
Mississippi (1)
Missouri (36)
Montana (9)
Nebraska (8)
Nevada (17)
New Hampshire (8)
New Jersey (1550)
New Mexico (7)
New York (994)
North Carolina (664)
North Dakota (2)
Northern California (1622)
Ohio (88)
Oklahoma (5)
Oregon (18)
Pennsylvania (777)
Puerto Rico (14)
Rhode Island (18)
South America (508)
South Carolina (10)
Southern California (1540)
Tennessee (59)
Texas (500)
United States (13879)
Utah (62)
Virginia (182)
Washington D.C. (42)
Washington State (246)
West Virginia (1)
Wisconsin (40)
Wyoming (1)
275,658 Results for "portola pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
November 10, 2025
·
7 min read
Press Releases
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
July 15, 2025
·
5 min read
Press Releases
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
March 24, 2025
·
6 min read
Press Releases
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
March 26, 2025
·
15 min read
Drug Development
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
October 17, 2024
·
5 min read
Press Releases
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
March 30, 2026
·
11 min read
Regulatory
Kezar’s Lupus Trial Paused After Four Patient Deaths
The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase IIa PORTOLA trial is ongoing.
October 7, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Otsuka Pharmaceutical to Acquire Transcend Therapeutics
March 27, 2026
·
8 min read
Press Releases
Faron Pharmaceuticals Ltd: Director Dealing
March 19, 2026
·
3 min read
Press Releases
60 Degrees Pharmaceuticals Announces 2025 Annual Results
March 31, 2026
·
6 min read
1 of 27,566
Next
